Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04519957 · ClinicalTrials.gov registry record
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
A clinical trial, sponsored by COMPASS Pathways.
- Completed
- Registry status
- 66
- Enrollment target
NCT04519957: Completed study, sponsored by COMPASS Pathways.
NCT04519957 is a clinical trial that has completed, run by COMPASS Pathways. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04519957 has completed, sponsored by COMPASS Pathways.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).
Primary Outcome
Use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2022-08-11 |
What the finished NCT04519957 record still lists
NCT04519957 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 66 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04519957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04519957 about?
NCT04519957 is a clinical study titled "Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)". The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 we...
What is the current status of trial NCT04519957?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2020-07-20. Estimated completion is 2022-08-11.
Who is sponsoring clinical trial NCT04519957?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI